The structure of NF-κB family proteins and their role in Apoptosis;Budowa białek z rodziny NF-κB i ich rola w procesie apoptozy

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 64-74

  Piotrowska, Aleksandra ^a   Izykowska, Ilona ^a   Podhorska Okołów, Marzena ^a   Zabel, Maciej ^a,b   Dzięgiel, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Uniwersytetu Medycznego   (Poland)

Author keywords

Apoptosis; IKK; I B; NF B; Signaling pathways to NF B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL; APOPTOSIS; CHEMISTRY; GENE EXPRESSION; GENETICS; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; GENE EXPRESSION; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 40749122602     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Aggarwal B.B.: Nuclear factor-κB: The enemy within. Cancer Cell, 2004; 6: 203-208
2. Aoki M., Nata T., Morishita R., Matsushita H., Nakagami H., Yamamoto K., Yamazaki K., Nakabayashi M., Ogihara T., Kaneda Y.: Endothelial apoptosis induced by oxidative stress through activation of NFkB. Antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension, 2001; 38: 48-55
3. Arends M.J., Wyllie A.H.: Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol., 1991; 32: 223-254
4. Ashkenazi A., Dixit V.M.: Death recepors: signaling and modulation. Science, 1998; 281: 1305-1308
5. Baichwal V.R., Baeuerle P.A.: Apoptosis: activate NF-κB or die? Curr. Biol., 1997; 7: R94-R96
6. Baldwin A.S.: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest., 2001; 107: 241-246
7. Beg A.A., Baltimore D.: An essential role for NF-κB in preventing TNF-A-induced cell death. Science, 1996; 274: 782-784
8. Beg A.A., Sha W.C., Bronson R.T., Ghosh S., Baltimore D.: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature, 1995; 376: 167-170
9. Beinke S., Ley S.C.: Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem. J., 2004; 382: 393-409
10. Ben-Neriah Y.: Regulatory functions of ubiquitination in the immune system. Nat. Immunol., 2002; 3: 20-26
11. Bentires-Alj M., Dejardin E., Viatour P., Van Lint C., Froesch B., Reed J.C., Merville M.P., Bours V.: Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines. Oncogene, 2001; 20: 2805-2813
12. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., Opipari A.W. Jr.: NF-κB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem., 2001; 276: 48921-48929
13. Birbach A., Gold P., Binder B.R., Hofer E., de Martin R., Schmid J.A.: Signaling molecules of the NF-κB pathway shuttle constitutively between cytoplasm and nucleus. J. Biol. Chem., 2002; 277: 10842-10851
14. Bonizzi G., Karin M.: The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol., 2004; 25: 280-288
15. Bottero V., Rossi F., Samson M., Mari M., Hofman P., Peyron J.F.: IkBa, the NF-κB inhibitory subunit, interacts with ANT, the mitochondrial ATP/ADP translocator. J. Biol. Chem., 2001; 276: 21317-21324
16. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., Siebenlist U.: The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell, 1993; 72: 729-739
17. Brown K., Park S., Kanno T., Franzoso G., Siebenlist U.: Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IkBa. Proc. Natl. Acad. Sci. USA, 1993; 90: 2532-2536
18. Campbell K.J., Witty J.M., Rocha S., Perkins N.D.: Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-κB transactivation. Cancer Res., 2006; 66: 929-935
19. Chen C., Edelstein L.C., Gélinas C.: The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol. Cell. Biol., 2000; 20: 2687-2695
20. Clarke P.G., Clarke S.: Historic apoptosis. Nature, 1995; 378: 230
21. Claudio E., Brown K., Park S., Wang H., Siebenlist U.: BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat. Immunol., 2002; 3: 958-965
22. Cohen J.J.: Apoptosis. Immunol. Today, 1993; 14: 126-130
23. Dechend R., Hirano F., Lehmann K., Heissmeyer V., Ansieau S., Wulczyn F.G., Scheidereit C., Leutz A.: The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene, 1999; 18: 3316-3323
24. Dejardin E., Droin, N.M., Delhase M., Haas E., Cao Y., Makris C., Li Z.W., Karin M., Ware C.F., Green D.R.: The lymphotoxin-b receptor induces different patterns of gene expression via two NF-κB pathways. Immunity, 2002; 17: 525-535
25. Deptała A., Nurzyńska D., Darzynkiewicz Z., Jędrzejczak W.W.: Rola białek z rodziny Rel/NFkB/IkB w patogenezie nowotworów. Post. Biol. Kom., 2002; 29: 489-504
26. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C.: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J., 1998; 17: 2215-2223
27. Dolcet X., Llobet D., Pallares J., Matias-Guiu X.: NF-κB in development and progression of human cancer. Virchows Arch., 2005; 446: 475-482
28. Dutta J., Fan Y., Gupta N., Fan G., Gélinas C.: Current insights into the regulation of programmed cell death by NF-κB. Oncogene, 2006; 25: 6800-6816
29. Escárcega R.O., Fuentes-Alexandro S., García-Carrasco M., Gatica A., Zamora A.: The transcription factor nuclear factor-kappa B and cancer. Clin. Oncol., 2007; 19: 154-161
30. Fiers W., Beyaert R., Declercq W., Vandenabeele P.: More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene, 1999; 18: 7719-7730
31. Fujita T., Nolan G.P., Liou H.C., Scott M.L., Baltimore D.: The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev., 1993; 7: 1345-1363
32. Garg A., Aggarwal B.B.: Nuclear transcription factor-κB as a target for cancer drug development. Leukemia, 2002; 16: 1053-1068
33. Ghosh S., Karin M.: Missing pieces in the NF-κB puzzle. Cell, 2002; 109: S81-S96
34. Ghosh S., May M.J., Kopp E.B.: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 1998; 16: 225-260
35. Gilmore T., Gapuzan M.E., Kalaitzidis D., Starczynowski D.: Rel/NFkêB/IkêB signal transduction in the generation and treatment of human cancer. Cancer Lett., 2002; 181: 1-9
36. Greten F.R., Karin M.: The IKK/NF-κB activation pathway-A target for prevention and treatment of cancer. Cancer Lett., 2004; 206: 193-199
37. Gupta R.A., Polk D.B., Krishna U., Israel D.A., Yan F., DuBois R.N., Peek R.M. Jr.: Activation of peroxisome proliferator-activated receptor g suppresses nuclear factor kB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J. Biol. Chem., 2001; 276: 31059-31066
38. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. Jr.: NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol., 1999; 19: 5785-5799
39. Harhaj E.W., Sun S.C.: Regulation of RelA subcellular localization by a putative nuclear export signal and p50. Mol. Cell. Biol., 1999; 19: 7088-7095
40. Haridas V., Shrivastava A., Su J., Yu G.L., Ni J., Liu D., Chen S.F., Ni Y., Ruben S.M., Gentz R., Aggarwal B.B.: VEGI, a new member of the TNF family activates nuclear factor-κB and c-Jun N-terminal kinase and modulates cell growth. Oncogene, 1999; 18: 6496-6504
41. Hayden M.S., Ghosh S.: Signaling to NF-κB. Genes Dev., 2004; 18: 2195-2224
42. Heusch M., Lin L., Geleziunas R., Greene W.C.: The generation of nfkb2 p52: mechanism and efficiency. Oncogene, 1999; 18: 6201-6208
43. Hong S.Y., Yoon W.H., Park J.H., Kang S.G., Ahn J.H., Lee T.H.: Involvement of two NF-κB binding elements in tumor necrosis factor a-, CD40-and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J. Biol. Chem., 2000: 275: 18022-18028
44. Huang T.T., Miyamoto S.: Postrepression activation of NF-κB requires the amino-terminal nuclear export signal specific to IkBa. Mol. Cell. Biol., 2001; 21: 4737-4747
45. Huxford T., Huang D.B., Malek S., Ghosh G.: The crystal structure of the IkBa/NF-κB complex reveals mechanisms of NF-κB inactivation. Cell, 1998; 95: 759-770
46. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schröter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J.: Inhibition of death receptor signals by cellular FLIP. Nature, 1997; 388: 190-195
47. Ivanov V.N., Ronai Z.: p38 protects human melanoma cells from UVinduced apoptosis through down-regulation of NF-κB activity and Fas expression. Oncogene, 2000: 19: 3003-3012
48. Kaltschmidt B., Kaltschmidt C., Hofmann T.G., Hehner S.P., Dröge W., Schmitz M.L.: The pro-or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus. Eur. J. Biochem., 2000; 267: 3828-3835
49. Karin M.: Nuclear factor-κB in cancer development and progression. Nature, 2006; 441: 431-436
50. Karin M., Ben-Neriah Y.: Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu. Rev. Immunol., 2000; 18: 621-663
51. Karin M., Cao Y., Greten F.R., Li Z.W.: NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2002; 2: 301-310
52. Karin M., Lin A.: NF-κB at the crossroads of life and death. Nat. Immunol., 2002; 3: 221-227
53. Kato T. Jr., Delhase M., Hoffmann A., Karin M.: CK2 is a C-terminal IkêB kinase responsible for NF-kêB activation during the UV response. Mol. Cell, 2003; 12: 829-839
54. Kitajima I., Soejima Y., Takasaki I., Beppu H., Tokioka T., Maruyama I.: Ceramide-induced nuclear translocation of NF-κB is a potential mediator of the apoptotic response to TNF-A in murine clonal osteoblasts. Bone, 1996; 19: 263-270
55. Kucharczak J., Simmons M.J., Fan Y., Gélinas C.: To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene, 2003; 22: 8961-8982
56. Kumar A., Takada Y., Boriek A.M., Aggarwal B.B.: Nuclear factorkB: its role in health and disease. J. Mol. Med., 2004; 82: 434-448
57. Lee S.H., Hannink M.: Characterization of the nuclear import and export functions of IkBe. J. Biol. Chem., 2002; 277: 23358-23366
58. Li Q., Verma I.M.: NF-êB regulation in the immune system. Nature, 2002; 2: 725-734
59. Li Z.W., Chu W., Hu Y., Delhase M., Deerinck T., Ellisman M., Johnson R., Karin M.: The IKKb subunit of IkB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J. Exp. Med., 1999; 189: 1839-1845
60. Lin L., DeMartino G.N., Greene W.C.: Cotranslational biogenesis of NF-κB p50 by the 26S proteasome. Cell, 1998; 92: 819-828
61. Lindström T.M., Bennett P.R.: The role of nuclear factor κB in human labour. Reproduction, 2005; 130: 569-581
62. Liu Z.G., Hsu H., Goeddel D.V., Karin M.: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell, 1996; 87: 565-576
63. abêdzka K., Grzanka A., Izdebska M.: Mitochondrium a mieræ komórki. Post. Hig. Med. Dow., 2006; 60: 439-446
64. Malek S., Chen Y., Huxford T., Ghosh G.: IkBb, but not IkBa, functions as a classical cytoplasmic inhibitor of NF-κB dimers by masking both NF-κB nuclear localization sequences in resting cells. J. Biol. Chem., 2001; 276: 45225-45235
65. Marienfeld R., May M.J., Berberich I., Serfling E., Ghosh S., Neumann M.: RelB forms transcriptionally inactive complexes with RelA/p65. J. Biol. Chem., 2003; 278: 19852-19860
66. Moynagh P.N.: The NF-κB pathway. J. Cell Sci., 2005; 118: 4589-4592
67. Mukhopadhyay A., Ni J., Zhai Y., Yu G.L., Aggarwal B.B.: Identification and characterization of a novel cytokine, THANK, a TNF homologue, that activates apoptosis, nuclear factor-κB, and c-Jun NH2-terminal kinase. J. Biol. Chem., 1999; 274: 15978-15981
68. Neurath M.F., Becker C., Barbulescu K.: Role of NF-κB in immune and inflammatory responses in the gut. Gut, 1998; 43: 856-860
69. O'Connor S., Shumway S.D., Amanna I.J., Hayes C.E., Miyamoto S.: Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkBa degradation in B cells. Mol. Cell. Biol., 2004; 24: 4895-4908
70. Olivier S., Robe P., Bours V.: Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem. Pharmacol., 2006; 72: 1054-1068
71. Perkins N.D.: Regulation of NF-κB by atypical activators and tumour suppressors. Biochem. Soc. Trans., 2004; 32: 936-939
72. Rocha S., Garrett M.D., Campbell K.J., Schumm K., Perkins N.D.: Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumor suppressor. EMBO J., 2005; 24: 1157-1169
73. Russo A., Terrasi M., Agnese V., Santini D., Bazan V.: Apoptosis: A relevant tool for anticancer therapy. Ann. Oncol., 2006; 17: vii115-vii123
74. Rutkowski R., Pancewicz S.A., Skrzydlewska E., Hermankowska-Szpakowicz T.: Waciwoci biologiczne czynnika transkrypcji jdrowej NF-κB. Alergia Astma Immunologia, 2005; 10: 125-131
75. Sasazuki T., Okazaki T., Tada K., Sakon-Komazawa S., Katano M., Tanaka M., Yagita H., Okumura K., Tominaga N., Hayashizaki Y., Okazaki Y., Nakano H.: Genome wide analysis of TNF-inducible genes reveals that antioxidant enzymes are induced by TNF and responsible for elimination of ROS. Mol. Immunol., 2004; 41: 547-551
76. Sen R., Baltimore D.: Inducibility of k immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell, 1986; 47: 921-928
77. Shao R., Hu M.C., Zhou B.P., Lin S.Y., Chiao P.J., von Lindern R.H., Spohn B., Hung M.C.: E1A sensitizes cells to tumor necrosis factorinduced apoptosis through inhibition of IkB kinases and nuclear factor κB activities. J. Biol. Chem., 1999; 274: 21495-21498
78. Sheikh M.S., Fornace A.J. Jr.: Death and decoy receptors and p53-mediated apoptosis. Leukemia, 2000; 14: 1509-1513
79. Shishodia S., Aggarwal B.B.: Nuclear factor-κB activation: A question of life and death. J. Biochem. Mol. Biol., 2002; 35: 28-40
80. Shu H.B., Takeuchi M., Goeddel D.V.: The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor signaling complex. Proc. Natl. Acad. Sci. USA, 1996: 93: 13973-13978
81. Siebenlist U., Franzoso G., Brown K.: Structure, regulation and function of NF-κB. Annu. Rev. Cell. Biol., 1994; 10: 405-455
82. Silverman N., Maniatis T.: NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev., 2001; 15: 2321-2342
83. Solan N.J., Miyoshi H., Carmona E.M., Bren G.D., Paya C.V.: RelB cellular regulation and transcriptional activity are regulated by p100. J. Biol. Chem., 2002; 277: 1405-1418
84. Stark L.A., Din F.V., Zwacka R.M., Dunlop M.G.: Aspirin-induced activation of the NF-κB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J., 2001; 15: 1273-1275
85. Tam W.F., Sen R.: IkB family members function by different mechanisms. J. Biol. Chem., 2001; 276: 7701-7704
86. Tergaonkar V.: NFęB pathway: A good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol., 2006; 38: 1647-1653
87. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.L., Schröter M., Scaffidi C., Krammer P.H., Peter M.E., Tschopp J.: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature, 1997; 386: 517-521
88. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., Baeuerle P.A.: Phosphorylation of human IkBa on serines 32 and 36 controls IkBa proteolysis and NF-κB activation in response to diverse stimuli. EMBO J., 1995; 14: 2876-2883
89. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M.: Suppression of TNF-A-induced apoptosis by NF-κB. Science, 1996; 274: 787-789
90. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. Jr.: NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol., 1999; 19: 5923-5929
91. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. Jr.: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998; 281: 1680-1683
92. Wydmuch Z., Więcławek A., Besser P., Mazurek U., Pytel A., Pacha J.: Leki przeciwzapalne blokujące aktywnos̈ć czynnika transkrypcyjnego NFkB. Poradnik farmaceutyczny, 2005; 5: 1-4
93. Xiao G., Fong A., Sun S.C.: Induction of p100 processing by NFkB-inducing kinase involves docking IkB kinase a (IKKa) to p100 and IKKa-mediated phosphorylation. J. Biol. Chem., 2004; 279: 30099-30105
94. Yamamoto M., Yamazaki S., Uematsu S., Sato S., Hemmi H., Hoshino K., Kaisho T., Kuwata H., Takeuchi O., Takeshige K., Saitoh T., Yamaoka S., Yamamoto N., Yamamoto S., Muta T., Takeda K., Akira S.: Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkBz. Nature, 2004; 430: 218-222
95. Yamamoto Y., Gaynor R.B.: Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest., 2001; 107: 135-142
96. Zingarelli B.: Nuclear factor-κB. Crit. Care Med., 2005; 33: S414-S416